Abstract
While the media and the public anxiously await the start of human trials with the angiogenesis inhibitor, endostatin, scientists are busy trying to understand the basic biology behind the delicate mechanisms that cause short bursts of blood vessel growth when needed and shut them off when the job is completed.

This publication has 0 references indexed in Scilit: